MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Organon & Co

Ouvert

SecteurSoins de santé

10.25 -3.3

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.2

Max

10.76

Chiffres clés

By Trading Economics

Revenu

-174M

-87M

Ventes

81M

1.6B

P/E

Moyenne du Secteur

4.03

35.739

BPA

1

Rendement du dividende

7.81

Marge bénéficiaire

-5.443

Employés

10,000

EBITDA

124M

449M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+36.79% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

7.81%

3.08%

Prochains Résultats

30 oct. 2025

Date du Prochain Dividende

11 déc. 2025

Date du Prochain Détachement de Dividende

11 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

304M

2.8B

Ouverture précédente

13.55

Clôture précédente

10.25

Sentiment de l'Actualité

By Acuity

50%

50%

183 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Organon & Co Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 oct. 2025, 16:58 UTC

Résultats

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 oct. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 oct. 2025, 20:44 UTC

Actions en Tendance

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct. 2025, 19:23 UTC

Acquisitions, Fusions, Rachats

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 oct. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 oct. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct. 2025, 14:52 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparaison

Variation de prix

Organon & Co prévision

Objectif de Prix

By TipRanks

36.79% hausse

Prévisions sur 12 Mois

Moyen 14.5 USD  36.79%

Haut 18 USD

Bas 11 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.53 / 9.18Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

183 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat